



Avexa Limited  
ABN 53 108 150 750  
576 Swan Street Richmond  
Victoria Australia 3121

Telephone 61 3 9208 4300  
Facsimile 61 3 9208 4004  
Website [www.avexa.com.au](http://www.avexa.com.au)

## ASX Release

13 March 2008

### AVEXA LIMITED BROADCAST

**AVEXA LIMITED (AVX)** provides the opportunity to listen to an audio broadcast with **Dr Julian Chick, CEO** in a presentation titled "**AVX - Avexa Reports Superior Results in ATC Phase 11b Trial Update- Dr Julian Chick, CEO**".

*To listen, simply click on the link below:*

<http://www.brr.com.au/event/43366>

The presentation details are as follows:

- **AVX - Avexa Reports Superior Results in ATC Phase 11b Trial Update- Dr Julian Chick, CEO**
- **Presented by Dr Julian Chick, CEO**
- **Thursday 13 March 2008 11.15AM AEST**

**Boardroomradio offers many free services, such as:**

- [Boardroomradio Alerts](#)
- Easy access to archived presentations on demand
- Podcast subscription with daily updates

Visit <http://www.brr.com.au> for more

#### **For more information:**

Dr. Julian Chick  
Chief Executive Officer  
+61 3 9208 4300

Mr Rod North  
Bourse Communications  
+ 61 (03) 9510-8309

[www.avexa.com.au](http://www.avexa.com.au)

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including its HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC), an anti-HIV drug which has successfully completed the 48 week dosing of its Phase 2b trial and has recently initiated Phase 3 trials. Avexa has entered into a collaboration with TargetDrug in China to identify new CCR5 inhibitors for the treatment of HIV.